A Randomized Double-Blind Placebo-Controlled Parallel-Group Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome

ID Number 14-0172

Principal Investigator(s)
Alexander Kolevzon

Department(s) or Division(s)
Psychiatry

Description

This is a Phase II randomized double-blind placebo-controlled parallel-group 42-day study to evaluate the safety and tolerability of NNZ-2566 in adolescent and adult males with Fragile X Syndrome. The primary objective of this study is to investigate the safety and tolerability of treatment with oral administration of NNZ-2566 35 mg/kg or 70 mg/kg BID versus placebo in adolescent and adult males (ages 14-40) with Fragile X Syndrome.



Contact Information
Stacey Lurie
(212) 241-3692
stacey.lurie@mssm.edu

Recruiting Patients: Yes